Premium
Disease Correction the iPSC Way: Advances in iPSC‐Based Therapy
Author(s) -
SanchoMartinez I,
Li M,
Izpisua Belmonte JC
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.341
Subject(s) - induced pluripotent stem cell , embryonic stem cell , regenerative medicine , stem cell , neuroscience , germ layer , medicine , population , biology , bioinformatics , microbiology and biotechnology , genetics , environmental health , gene
Pluripotent stem cells possess the capacity for self‐renewal and the ability to differentiate into all cell types of the three embryonic germ layers. Accordingly, given their potential use in regenerative medicine, they have long attracted the attention of researchers. Embryonic stem cells (ESCs) represent the model pluripotent stem cell population. However, the use of ESCs in regenerative therapies faces major hurdles—namely, immune rejection and the necessity to use early‐stage embryos for ESC isolation. Clinical Pharmacology & Therapeutics (2011) 89 5, 746–749. doi: 10.1038/clpt.2010.341